BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 16043984)

  • 1. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
    Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Erythrocyte Sedimentation Rate and C-Reactive Protein With Pediatric Inflammatory Bowel Disease Activity.
    Alper A; Zhang L; Pashankar DS
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):e25-e27. PubMed ID: 27741061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases?
    Kaplan M; Yuksel M; Ates I; Kilic ZM; Kilic H; Kuzu UB; Kayacetin E
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1120-5. PubMed ID: 26642816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
    Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease.
    Rodgers AD; Cummins AG
    Dig Dis Sci; 2007 Sep; 52(9):2063-8. PubMed ID: 17436102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-enhanced magnetic resonance imaging: a useful radiological tool in diagnosing pediatric IBD.
    Darbari A; Sena L; Argani P; Oliva-Hemker JM; Thompson R; Cuffari C
    Inflamm Bowel Dis; 2004 Mar; 10(2):67-72. PubMed ID: 15168803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet/Albumin ratio and plateletcrit levels are potential new biomarkers for assessing endoscopic inflammatory bowel disease severity.
    Huang J; Lu J; Jiang F; Song T
    BMC Gastroenterol; 2023 Nov; 23(1):393. PubMed ID: 37964205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.
    Farias E Silva K; Nanini HF; Cascabulho CM; Rosas SLB; Santana PT; Carneiro AJV; Anaissie E; Nucci M; de Souza HSP
    World J Gastroenterol; 2021 Mar; 27(9):866-885. PubMed ID: 33727775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.
    Cordes F; Demmig C; Bokemeyer A; Brückner M; Lenze F; Lenz P; Nowacki T; Tepasse P; Schmidt HH; Schmidt MA; Cichon C; Bettenworth D
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00134. PubMed ID: 32352717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
    Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
    Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.
    Kalla R; Kennedy NA; Ventham NT; Boyapati RK; Adams AT; Nimmo ER; Visconti MR; Drummond H; Ho GT; Pattenden RJ; Wilson DC; Satsangi J
    Am J Gastroenterol; 2016 Dec; 111(12):1796-1805. PubMed ID: 27596694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease.
    Mak LY; Tong TSM; Cheung KS; Chen LJ; Lui KL; Lau KS; Leung WK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00138. PubMed ID: 32132451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.